EULAR/ACR SLE classification criteria were not linked to mortality or hospitalization, a developed ominosity model adequately predicted mortality.

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of ...

The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene ...

found that 27% of individuals with systemic lupus erythematosus (SLE) had hearing loss. This was significantly higher than in the control group. Participants with SLE showed worse hearing at lower ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

Since 2008, when the first EULAR recommendations for the management of systemic lupus erythematosus (SLE) were published and widely adopted,1 a series of specific recommendations on disease monitoring ...

Systemic lupus erythematosus (SLE) is a latent, insidious autoimmune disease, and with the development of gene sequencing in recent years, our study aims to develop a gene-based predictive model to ...

Your trusted source for the latest news delivered weekdays from the team at U.S. News and World Report. Sign in to manage your newsletters » Sign up to receive the latest updates from U.S News ...

This advertisement has not loaded yet, but your article continues below.

This advertisement has not loaded yet, but your article continues below.

This advertisement has not loaded yet, but your article continues below.